undamentalytics Newsletter
Sign in

Work Medical Technology Group LTD (WOK) stock

Add to watchlist

Add holding +

NASDAQ: WOK Nasdaq Health Care Equipment

C+ Fundamentals grade

Work Medical Technology Group LTD is a US-listed company in the health care equipment industry. Its financial year ends in September.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$0.8

Revenue-to-maturity cash-flow model

Base case. Range ~$0.8–$1.0 across our lower- and higher-growth cases (0%–5% a year).

Price vs value

No Buy/Hold/Sell rating is issued: only 2 valuation models apply; a rating needs 3.

Work Medical Technology Group LTD valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders1 buying, 1 selling10 purchases and 5 sales by directors and officers, last 12 monthsInsider trades
  • Funds3 adding, 0 cuttingOf 0 active managers that changed their stake, 0 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Work Medical Technology Group files

Where Work Medical Technology stands after its latest Filing

Revenue for the twelve months was $10m. That puts it 119 of 129 for growth among the health care equipment companies we cover. Free-cash-flow margin held at 49.9%. The diluted share count is up 128.1% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades C+. It passes 2 of our 2 financial-health checks. Our revenue-to-maturity cash-flow model value is $0.81 a share, against a share price of $1.00.

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Work Medical Technology Group LTD's trailing-twelve-month revenue fell 14.4% year on year, with a free-cash-flow margin of 49.9%. Where it stands out: free-cash-flow margin of 49.9% ranks 1 of 128 health care equipment companies we cover. Where it lags: change in share count of 128.1% ranks 113 of 115 health care equipment companies we cover.

Current signal Share count rising (dilution): Diluted shares outstanding rose 128.1% year over year.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Strong cash generation. 49.9% of revenue turned into free cash flow, against a median of -3.4% for health care equipment companies we cover.
  • Net cash. Cash exceeds long-term debt by $0.0bn.

Things to watch

  • Revenue shrinking. Revenue fell 14.4% over the last 12 months.
  • Share dilution. Diluted shares rose 128.1% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 299% and a beta of 1.8 against the S&P 500.
  • Below peers: gross margin. Gross margin of 23.8% ranks 112 of 123 health care equipment companies we cover (median 61.9%).

Price chart

  • 1 day0.0%
  • 1 week-11.5%
  • 1 month-41.5%
  • This year-99.5%
  • 1 year-100.0%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$9.8M
Net margin
-10.9%
EPS (TTM, diluted)
$-0.04

Growth

Revenue growth
−14.4%
Change in growth rate
+0.8 pts
Share count change
+128.1%

Cash

Free cash flow (TTM)
$4.9M
FCF margin
49.9%

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

No recent updates are available for WOK from the sources we follow. See filings →

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Work Medical Technology Group LTD valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: only 2 valuation models apply; a rating needs 3.

Valuation models

We value Work Medical Technology Group LTD as an operating company, with every model that fits that kind of business. Cost of equity 12.4%: the 10-year Treasury yield (4.9%) plus a beta of 1.65 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. ~$0.8 ~$0.8–$1.0 Primary model, counts double
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — 0 Does not apply: no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. ~$0.3 ~$0.4–$1.7 Included, half weight
Combined value Weighted average of the models that apply: the primary model (revenue-to-maturity model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$0.7 ~$0.3–$0.8 2 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Work Medical Technology Group LTD with Health Care Equipment in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20242025
Share price$5140000.00$75000.00
Market value$65.30tn$2.17tn
+ Net debt (− = net cash)$7m$2m
Enterprise value$65.30tn$2.17tn
Multiples
Price / sales n/mn/m
Price / earnings ——
Price / free cash flow —n/m
EV / EBITDA ——

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Low.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

No analyst estimates are published for Work Medical Technology Group LTD: too few analysts cover it.

Positioning

Short interest
3.2%
of tradable shares
Days to cover
2.96
at average volume
Short interest, 1 month
+2%
to October 15, 2026
Held by institutions
0%
of shares
Held by insiders
0.0%
of shares
Employees
238
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Recent prices are available. Older price history and the statistics that need it are being loaded in the background.

Return and risk by year

Calendar year 20252026 to date
Return
WOK−100%−100%
Industry peers (median)−16%−13%
S&P 500+18%+11%
Months that ended higher
WOK33%27%
S&P 50075%46%
Largest fall from a high during the year
WOK−100%−100%
S&P 500−19%−9%

Worst fall since August 23, 2024: 100% from September 4, 2024 to October 30, 2026. Getting back needed a 756999900% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$1.00 – $70700.00
From 52-week high
−100.0%
vs 50-day average
−40.7%
vs 200-day average
−98.4%
Volatility (1 year)
299%
Beta vs S&P 500
1.83

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Work Medical Technology Group LTD in five measures

Fundamentals grade C+
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Work Medical Technology Group LTD
$5M $10M $15M $20M FY22 Q4 FY23 Q4 FY24 Q4 FY25 Q4 Revenue (TTM), FY22 Q4: $19.7M Revenue (TTM), FY23 Q4: $13.6M Revenue (TTM), FY24 Q4: $11.5M Revenue (TTM), FY25 Q4: $9.8M $9.8M

Source: SEC EDGAR filings. Retrieved Invalid Date.

View chart data
Period Revenue (TTM)
FY22 Q4 $19.7M
FY23 Q4 $13.6M
FY24 Q4 $11.5M
FY25 Q4 $9.8M
FCF margin (TTM) Work Medical Technology Group LTD
-100% -50% 0% 50% FY22 Q4 FY23 Q4 FY24 Q4 FY25 Q4 FCF margin (TTM), FY22 Q4: -21.7% FCF margin (TTM), FY23 Q4: 12.9% FCF margin (TTM), FY24 Q4: -99.5% FCF margin (TTM), FY25 Q4: 49.9% 49.9%

Source: SEC EDGAR filings. Retrieved Invalid Date.

View chart data
Period FCF margin (TTM)
FY22 Q4 -21.7%
FY23 Q4 12.9%
FY24 Q4 -99.5%
FY25 Q4 49.9%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 20-F. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2022 Sept 2022 2023 Sept 2023 2024 Sept 2024 2025 Sept 2025
Income
Revenue 20 14 12 10
Gross profit 4 4 3 2
Net income 1 0 −3 −1
Diluted EPS $0.07 $0.01 −$0.27 −$0.04
Growth (year on year)
Revenue — −31.2% −15.2% −14.4%
Net income — −87.1% — —
Diluted EPS — −85.7% — —
Margins
Gross margin 22.4% 30.5% 24.9% 23.8%
Net margin 4.4% 0.8% −30.4% −10.9%
Free-cash-flow margin −21.7% 12.9% −99.5% 49.9%
Cash flow
Cash from operations −2 2 −2 6
Capital spending 2 0 9 1
Free cash flow −4 2 −11 5
Balance sheet
Cash 1 2 7 4
Total debt 0 9 13 6
Net debt (negative = net cash) −1 7 7 2
Diluted shares 13m 13m 13m 29m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 2 checks passed · September 30, 2025
What it owns · $33m
Short-term assets $20mLonger-term assets $13m
What it owes, and who funded it · $30m
Short-term liabilities $12mLonger-term liabilities $0mShareholders' equity $18m
  • Short-term assets cover short-term liabilities $20m of assets due within a year against $12m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $20m short-term assets against $20,059 of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Work Medical Technology Group LTD's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+128.1%
year over year
R&D spending
4.4%
of revenue
Days sales outstanding
23 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in health care equipment
Last 12 months unless stated WOK NMTC MLSS NUWE NSPR NNNN Median
Revenue, last 12 months $10m $9m $9m $9m $11m $9m $99m
Revenue growth, last 12 months −14.4% 42.8% 3.7% 8.4% 53.4% 5.6% 9.2%
Revenue growth, 3-year average — 94.9% −1.9% 2.8% 26.6% — 13.5%
Revenue growth, latest quarter — 16.3% 22.3% 14.1% −0.4% — 10.2%
Gross margin 23.8% 55.6% 70.2% 69.7% 18.1% 87.2% 61.2%
Operating margin — −83.4% −43.6% −142.9% −494.0% 66.7% −8.5%
Operating margin, 3-year average — −160.3% −66.8% −138.4% −501.9% — −17.9%
Net margin −10.9% −78.6% −44.0% −125.6% −484.1% 74.1% −12.0%
Cash from operations / revenue 63.4% −74.5% −6.8% −138.3% −380.1% −77.9% −1.9%
Free-cash-flow margin 49.9% −75.6% −7.0% −139.7% −391.7% — −3.9%
Free-cash-flow margin, 3-year average — −142.5% −53.1% −126.7% −372.4% — −7.0%
Stock pay / revenue — 14.9% 10.3% 1.0% 98.8% — 6.1%
Change in share count 128.1% 41.1% 5.9% 5.4% 63.5% 3.3% 4.0%

Median of all 134 companies we cover in health care equipment. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

134 health care equipment companies
Measure Company Peer median Rank
Revenue growth Growth -14.4% 9.1% 119 of 129
Change in growth rate Growth +0.8pp -0.6pp 45 of 129
Gross margin Profitability 23.8% 61.9% 112 of 123
Net margin Profitability -10.9% -12.0% 65 of 133
Free-cash-flow margin Cash generation 49.9% -3.4% 1 of 128
Change in share count Balance sheet 128.1% 3.3% 113 of 115
Days sales outstanding Balance sheet 23 days 57 days 6 of 118

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Who owns it

Funds buying and selling
Reported value
$21,049
Institutions reporting
3
Positions opened / closed
3 / 0

Top buyers and sellers, Q2 2026: 3 institutions bought and 0 sold ; the biggest buyer was UBS Group AG (+10K shares) . See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
UBS Group AG $20,082 10K 95.4% —
Tower Research Capital LLC (TRC) $770 0K 3.7% —
North Star Investment Management Corp. $197 0K 0.9% —

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Work Medical Technology Group LTD's complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $1.4M 10 trades by 1 insider, last 12 months Insider sales History → $1.5M 5 trades by 1 insider · 0% under pre-set plans
Net ▼ $178,450 net selling
Insider Date Trade Shares Price Value
Hrt Financial Lp 10% owner June 18, 2026 Sell 136,665 $3.87 $528,894
Hrt Financial Lp 10% owner June 17, 2026 Buy 880,456 $0.05 $44,023
Hrt Financial Lp 10% owner June 16, 2026 Sell 2,904,567 $0.06 $174,274
Hrt Financial Lp 10% owner June 15, 2026 Buy 268,927 $0.10 $26,893
Hrt Financial Lp 10% owner June 12, 2026 Buy 48,108 $0.08 $3,849
Hrt Financial Lp 10% owner June 11, 2026 Buy 2,029,327 $0.09 $182,639
Hrt Financial Lp 10% owner June 10, 2026 Buy 1,765,384 $0.10 $176,538
Hrt Financial Lp 10% owner June 9, 2026 Sell 3,463,022 $0.11 $380,932
Hrt Financial Lp 10% owner June 8, 2026 Buy 2,261,118 $0.11 $248,723
Hrt Financial Lp 10% owner June 5, 2026 Buy 54,529 $0.09 $4,908
Hrt Financial Lp 10% owner June 4, 2026 Buy 1,370,008 $0.11 $150,701
Hrt Financial Lp 10% owner June 2, 2026 Sell 1,757,955 $0.11 $193,375

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Data status

When each part of this page on Work Medical Technology Group LTD was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Work Medical Technology Group LTD in brief

What does Work Medical Technology Group LTD do?
Work Medical Technology Group LTD is a US-listed company in the health care equipment industry. Its financial year ends in September.
What is Work Medical Technology Group LTD's stock ticker?
Work Medical Technology Group LTD trades under the ticker WOK on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Work Medical Technology Group LTD's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Work Medical Technology Group LTD reported revenue of $9.8M, 14.4% lower than a year earlier, according to its SEC filings.
What is Work Medical Technology Group LTD's free cash flow?
Work Medical Technology Group LTD's free-cash-flow margin is 49.9% of revenue over the trailing twelve months, ranking 1 of the 128 health care equipment companies we cover.
Who are Work Medical Technology Group LTD's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are UBS Group AG, Tower Research Capital LLC (TRC) and North Star Investment Management Corp. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Work Medical Technology Group LTD's market cap?
On September 30, 2025, Work Medical Technology Group LTD's market capitalisation was about $2.2T and net debt of $2.3M. Market figures come from third-party market data and may be delayed.
Who are Work Medical Technology Group LTD's competitors?
In our Health Care Equipment peer group, the companies closest to Work Medical Technology Group LTD are Neuroone Medical Technologies Corp, Milestone Scientific Inc., Nuwellis, Inc., Inspiremd, Inc. and Anbio Biotechnology. The side-by-side comparison below sets their revenue, margins and growth against Work Medical Technology Group LTD's.
Are insiders buying or selling Work Medical Technology Group LTD stock?
Over the last 12 months, Work Medical Technology Group LTD's directors and officers reported 10 open-market purchases and 5 sales on Form 4. The insider trading page charts every trade.